ABMC Reports First Quarter 2019 Results

KINDERHOOK, NY / ACCESSWIRE / May 20, 2019 / American Bio Medica Corporation (OTC PINK: ABMC) today announced financial results for the three months ended March 31, 2019.

Chief Executive Officer Melissa A. Waterhouse stated, “New contract manufacturing sales and increased sales of products offered through distribution relationships partially offset lost government sales in the first quarter 2019 when compared to the first quarter 2018. International sales were also down in the first quarter 2019; most of which we believe is due to timing of orders. Expenses remained in line with sales and this allowed us to report a slight improvement in result from operations.”

Financial Highlights

  • Net sales in the first quarter 2019 were $923,000, compared to net sales of $1,041,000 in the first quarter 2018, a decrease of $118,000, or 11.3%.
  • Operating loss was $174,000 in the first quarter 2019, compared to an operating loss of $206,000 in the first quarter 2018.
  • Net loss was $240,000 in the first quarter 2019, or $(0.01) per share, compared to a net loss of $267,000, or $(0.01) per share, in the first quarter 2018.

For more information on ABMC or its drug testing products, please visit www.abmc.com.

About American Bio Medica Corporation

American Bio Medica Corporation manufactures and markets accurate, cost-effective immunoassay test kits, primarily point of collection tests for drugs of abuse. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC’s Rapid Drug Screen®, Rapid ONE®, RDS® InCup®, Rapid TOX® and Rapid TOX Cup® II test for the presence or absence of drugs of abuse in urine, while OralStat® tests for the presence or absence of drugs of abuse in oral fluids. ABMC’s Rapid Reader® is a compact, portable device that, when connected to any computer, interprets the results of an ABMC drug screen, and sends the results to a data management system, enabling the test administrator to easily manage their drug testing program.

This release may contain forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, risks and uncertainties related to the following: continued acceptance of our products, increased levels of competition in our industry, acceptance of new products, product development, compliance with regulatory requirements, including but not limited to our ability to obtain marketing clearance on our product for our intended markets, intellectual property rights, our dependence on key personnel, third party sales and suppliers, trading in our common shares may be subject to “penny stock” rules, our history of recurring net losses and our ability to continue as a going concern. There can be no assurance that the Company will be successful in addressing such risks and uncertainties and the Company assumes no duty to update any forward-looking statements based upon actual results. Investors are strongly encouraged to review the section entitled “Risk Factors” in the Company’s annual report on Form 10-K for the year ended December 31, 2018, quarterly reports on Form 10-Q, and other periodic reports on file with the Securities and Exchange Commission for a discussion of risks and uncertainties that could affect operating results and the market price of the Company’s common shares.


Condensed Statements of Operations

For the three
For the three
months ended
months ended
March 31, 2019
March 31, 2018
Net sales
$ 923,000 $ 1,041,000
Cost of goods sold
617,000 669,000
Gross profit
306,000 372,000
Operating expenses:
Research and development
19,000 25,000
Selling and marketing
113,000 161,000
General and administrative
348,000 392,000
Total operating expenses
480,000 578,000
Operating loss
(174,000 ) (206,000 )
Other expense
(66,000 ) (61,000 )
Net loss before tax
(240,000 ) (267,000 )
Income tax expense
0 0
Net loss
$ (240,000 ) $ (267,000 )
Basic & diluted (loss) / income per common share
$ (0.01 ) $ (0.01 )
Weighted average shares outstanding – basic
32,367,963 29,882,770
Weighted average shares outstanding – diluted
32,367,963 29,822,770

American Bio Medica Corporation
Condensed Balance Sheets

March 31,
December 31,
Current Assets
Cash and cash equivalents
$ 54,000 $ 113,000
Accounts receivable, net of allowance for doubtful accounts of $36,000 at both March 31, 2019 at December 31, 2018
392,000 452,000
Inventory, net of allowance of $276,000 at March 31, 2019 and $268,000 at December 31, 2018
973,000 1,019,000
Prepaid expenses and other current assets
48,000 29,000
Total current assets
1,467,000 1,613,000
Property, plant and equipment, net
699,000 718,000
Patents, net
121,000 123,000
Other assets
29,000 21,000
Total assets
$ 2,316,000 $ 2,475,000
Current liabilities
Accounts payable
$ 521,000 $ 359,000
Accrued expenses and other current liabilities
440,000 449,000
Wages payable
276,000 278,000
Line of credit
421,000 502,000
Current portion of long-term debt

1,013,000 237,000
Total current liabilities
2,671,000 1,825,000
Long-term debt/other liabilities, net of deferred finance costs
12,000 796,000
Total liabilities
2,683,000 2,621,000
Stockholders’ Equity:
Common stock
325,000 323,000
Additional paid-in capital
21,421,000 21,404,000
Accumulated deficit
(22,113,000 ) (21,873,000 )
Total stockholders’ equity
(367,000 ) (146,000 )
Total liabilities and stockholders’ equity
$ 2,316,000 $ 2,475,000


Melissa A. Waterhouse
Chief Executive Officer
(800) 227-1243, Ext 107

SOURCE: American Bio Medica Corporation

View source version on accesswire.com:

error: Content is protected !!